Black Hawk Acquisition (BKHA) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MiNK Therapeutics is the larger company by market cap ($54.7 million vs $47.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | INKT |
|---|---|---|
| Share price | $11.53 | $10.72 |
| Market cap | $47.89M | $54.70M |
| 1-day change | -6.49% | -2.55% |
| YTD return | — | -1.35% |
| 1-year return | — | -24.61% |
| 5-year return | — | -90.83% |
| P/E ratio (TTM) | 34.94 | — |
| EPS (TTM) | $0.33 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $16.93 |
| 52-week low | $11.00 | $8.48 |
| Distance from 52-week high | -12.32% | -36.67% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +263.81% |
| Average volume | 5.83K | 13.80K |
| Shares outstanding | 4.15M | 5.10M |
| Employees | — | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
BKHA vs INKT FAQ
Which is bigger, Black Hawk Acquisition or MiNK Therapeutics?
MiNK Therapeutics (INKT) is larger, with a market capitalization of $54.70M compared with $47.89M for Black Hawk Acquisition (BKHA).
Are Black Hawk Acquisition and MiNK Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.